Ixazomib clinical trials
Also written MLN9708, Ninlaro and MLN2238.
Related medicines add 1 study
Counted the way a researcher would: Ixazomib with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses ixazomib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ixazomib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Nov 2015 · NINLARO · NDA 208462 (FDA, Drugs@FDA)
- European Union
- 21 Nov 2016 · Ninlaro · EMEA/H/C/003844 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
125 studies that test it; most in 2015 (20)
| Year | Studies |
|---|---|
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 16 |
| 2015 | 20 |
| 2016 | 14 |
| 2017 | 12 |
| 2018 | 15 |
| 2019 | 14 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 93
Millennium Pharmaceuticals, Inc. (19) · Takeda (11) · M.D. Anderson Cancer Center (9) · Mayo Clinic (9) · National Cancer Institute (NCI) (4) · Emory University (4) · Memorial Sloan Kettering Cancer Center (3) · Fred Hutchinson Cancer Center (2)
Often tested with
Tested in the same studies.
Dexamethasone (34) · Lenalidomide (17) · Daratumumab (11) · Pomalidomide (8) · Rituximab (4) · Venetoclax (3) · Bortezomib (2) · Ibrutinib (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
- One of Proteasome inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test ixazomib.
- Dec 2026Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMPhase 2 · Alliance Foundation Trials, LLC.
- Aug 2027Ixazomib Maintenance Study in Patients With AL AmyloidosisPhase 2 · Memorial Sloan Kettering Cancer Center
- Oct 2027A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizePhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Oct 2027Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses ixazomib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 125
- A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizeNot yet recruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07881809Written as Ixazomib 4 mg
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05722405Written as Ixazomib plus low-dose lenalidomide
- Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)RecruitingPhase 2Ho Sup LeeNCT03616782Written as Ixazomib
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04847453Written as Ixazomib Citrate
- Ixazomib Maintenance Study in Patients With AL AmyloidosisActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03618537Written as Ixazomib
- Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingPhase 2Washington University School of MedicineNCT02253316Written as Ixazomib
- Trial of Ixazomib for Kaposi SarcomaActive, not recruitingPhase 2AIDS Malignancy ConsortiumNCT04305691Written as Ixazomib Citrate
- Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple MyelomaCompletedPhase 1/2Joseph TuscanoNCT02542657Written as Ixazomib Citrate
- Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedPhase 1/2City of Hope Medical CenterNCT02119468Written as ixazomib citrate
- Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03763162Written as Ixazomib
- Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedPhase 2Fred Hutchinson Cancer CenterNCT02619682Written as Ixazomib Citrate
- Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)CompletedPhase 2Nantes University HospitalNCT01936532Written as MLN9708
- Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT03587662Written as Ixazomib
- Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisCompletedPhase 1M.D. Anderson Cancer CenterNCT03283917Written as Ixazomib
- Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 2University of WashingtonNCT02339922Written as Ixazomib Citrate
- Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedPhase 3Alliance for Clinical Trials in OncologyNCT02516423Written as ixazomib
- A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaCompletedPhase 1/2PrECOG, LLC.NCT03323151Written as Ixazomib
- Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibCompletedPhase 2Mayo ClinicNCT01415882Written as Ixazomib Citrate
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedPhase 3CelgeneNCT03651128Written as Ixazomib
- Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple MyelomaTerminatedPhase 2University Hospital, CaenNCT03757221Written as Ixazomib and Daratumumab
See all 125 studies that test ixazomib →
Given beside what is tested · 16 — ixazomib is usual care or a partner of the new treatment
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Ixazomib
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Ixazomib
- Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedPhase 2Larysa SanchezNCT04052880Written as Ixazomib
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Active, not recruitingPhase 2Nantes University HospitalNCT04998786Written as Ixazomib
- Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma PatientsActive, not recruitingPhase 2Raija SilvennoinenNCT03376672Written as Ixazomib
- Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnPhase 1/2Kathleen DorritieNCT06050512Written as Ixazomib
- Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedPhase 1/2Mayo ClinicNCT02633059Written as Ixazomib Citrate
- STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSCompletedPhase 2Mario BoccadoroNCT02586038Written as MLN9708
- Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedPhase 2Mayo ClinicNCT03506360Written as Ixazomib Citrate
- Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaActive, not recruitingPhase 1/2Alliance for Clinical Trials in OncologyNCT02004275Written as ixazomib
- Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibTerminatedPhase 1/2H Scott BoswellNCT04079738Written as Ixazomib
- A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnPhase 4TakedaNCT05183139Written as Ixazomib
- A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02831686Written as Ixazomib
- Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedPhase 1/2Parameswaran HariNCT02477215Written as MLN9708
- Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedPhase 1/2Ajai ChariNCT03492138Written as Ixazomib
- Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnPhase 1/2National Cancer Institute (NCI)NCT03856112Written as Ixazomib
As the comparator · 2 — what is tested is compared with ixazomib
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisActive, not recruitingPhase 1/2Columbia UniversityNCT05451771Written as Ixazomib
- IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaCompletedPhase 3Millennium Pharmaceuticals, Inc.NCT01850524Written as Ixazomib
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Codes
What other systems call ixazomib · ClinicalTrials.gg INT005598
- MeSH (NLM) C548400ixazomibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 71050168A2IXAZOMIBConfirmed FDA, NLM, Wikidata
- RxNorm 1723735Confirmed FDA, Wikidata
- Wikidata Q20948663ixazomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97940IxazomibOne source FDA
- DrugBank DB09570One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C548400 | ixazomib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 71050168A2 | IXAZOMIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1723735 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20948663 | ixazomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97940 | Ixazomib | One source FDA |
| DrugBank | DB09570 | — | One source Wikidata |
Also registered as ixazomib citrate (UNII 46CWK97Z3K · RxNorm 1723734).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.